2714 (2714) Fair Value & Analysis

Consumer Defensive · Market cap HK$184B

2 2714 2714 · HK

PriceHK$31.94

Fair ValueHK$52.68

Upside+64.9%

Quality56/100

Watch 2714 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$39.46 – HK$72.46

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −9.4% over the past month.

Price vs Fair Value (5 months)

5‑month range HK$27.96 – HK$46.81 · fair‑value band HK$39.46 – HK$72.46 · the HK$31.94 price screens below the HK$52.68 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2714 (2714) currently trades at HK$31.94, while our model-based Fair Value estimate is HK$52.68 — implying the stock looks roughly 64.9% undervalued today. We read business quality at 56/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2714 generated revenue of HK$138B at a net margin of 7.1%. Revenue declined 17.1% year over year. It earns a return on equity of 11.9%. Net debt stands at HK$46.7B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$138B

Revenue growth (YoY) -17.1%

Net margin 7.1%

Return on equity 11.9%

Free cash flow HK$20.5B FY2025

P/E ratio 15.4

More key figures

Operating margin -0.2%

EPS (TTM) HK$-0.2483

Dividend yield 4.7%

Net debt HK$46.7B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2025 · reported fiscal years

2714 reported revenue of HK$144B in FY2025 versus HK$125B in FY2022, a compound +4.9%/yr. Reported net income was HK$15.5B in FY2025, compounding +5.3%/yr from FY2022.

Revenue +4.9%/yr

FY22 HK$125B

FY23 HK$111B

FY24 HK$138B

FY25 HK$144B

Net income +5.3%/yr

FY22 HK$13.3B

FY23 −HK$4.3B

FY24 HK$17.9B

FY25 HK$15.5B

Is 2714 fairly valued? → Check now

Similar stocks

6 more Farm Products stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Archer-Daniels-Midland Company ADM	$81.28	$38.31	-53%
MHP SE MHPC	$0.0854	$0.0100	-88%
Muyuan Foods Group 002714	¥33.95	¥119.07	+251%
Bunge Global SA BG	$129.13	$136.85	+6%
Tyson Foods, Inc TSN	$58.73	$34.80	-41%
Wens Foodstuff Group 300498	¥12.89	¥6.35	-51%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2714 (2714) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$52.68 versus a price of HK$31.94 — about +65% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2714?

Our model-based fair value for 2714 is HK$52.68 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$31.94.

What is the quality score of 2714?

2714 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2714 (2714)?

2714 reported trailing-twelve-month revenue of about HK$138B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2714?

The net profit margin of 2714 is about 7.1%, meaning it keeps roughly 7.1% of revenue as net income. Based on the latest reported figures.

Does 2714 pay a dividend?

2714 currently shows a dividend yield of about 4.68% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.